Compare iShares MSCI Canada (TSX) (EWC) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Incyte Corporation — how do they compare? iShares MSCI Canada (TSX) trades at $58.3 (market cap $6.99B), while Incyte Corporation trades at $112.8 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 3.3× iShares MSCI Canada (TSX)'s market cap, and Incyte Corporation is more actively traded (1,927,029 versus 1,625,847). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Canada (TSX) for 57 Days and Incyte Corporation for 33 Days on average.
| EWC | INCY | |
|---|---|---|
Market Cap | $6.99B | $22.85B |
Volume | 1,625,847 | 1,927,029 |
Sector | Broad Market / Factor | Health |
52-Week High | $62.64 | $129.93 |
52-Week Low | $49.72 | $83.80 |
Typical Hold Time | 57 Days | 33 Days |
Enterprise Value | — | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $57.94, down 2.1% today amid a bearish technical signal with moving averages indicating selling pressure. The stock lacks disclosed financial ratios, limiting fundamental clarity. Recent news highlights trade tensions between the U.S. and Canada, with potential impacts on cross-border economic activity and market sentiment.
The outlook is clouded by geopolitical risks from U.S.-Canada trade disputes, which could pressure performance. Investment opportunities hinge on resolution of trade frictions and improved economic data. Key risks include prolonged trade uncertainty and volatility from political developments.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
